Opendata, web and dolomites

MUC SIGNED

The microbial degradation and utilization of mucin by Bacteroides in ulcerative colitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MUC" data sheet

The following table provides information about the project.

Coordinator
GOETEBORGS UNIVERSITET 

Organization address
address: VASAPARKEN
city: GOETEBORG
postcode: 405 30
website: www.gu.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.medkem.gu.se/mucinbiology/
 Total cost 247˙059 €
 EC max contribution 247˙059 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GOETEBORGS UNIVERSITET SE (GOETEBORG) coordinator 247˙059.00
2    UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN US (ANN ARBOR) partner 0.00

Map

 Project objective

The gastrointestinal tract is colonized by a community of microbes, the microbiota, which has a significant impact on human health and nutrition. The mucus gel layer structure provides the barrier between the microbiota and the intestine preventing the occurrence of the inflammation process. Indeed, an altered microbiota (towards mucus degrading bacteria) and defects in the mucus structure have been shown to be associated with inflammatory bowel diseases, such as ulcerative colitis. Understanding how members of the microbiota can alter mucin composition, can, potentially, be deployed to ensure that the structure of this ecosystem maximizes human health. This approach, however, is limited by a lack of understanding how mucins are metabolized by the microbiota. Significantly, available genomic/metagenomics sequence data of the microbiota presents an exciting, but so far, unfulfilled, opportunity to make decisive advances in our understanding of mucin degradation by members of this ecosystem. In this project I will seek to combine this genomic information with in vivo studies to understand the mechanisms of mucin utilization by the human microbiota and the impact on UC development. The data from the research programme will underpin the development of future therapeutic strategies to improve human health. The fellow is Portuguese and is now completing her PhD at the Newcastle University, UK. The fellow has experience in enzyme activity screening, enzymatic characterization and structural biology. In this fellowship she will have the opportunity to develop skills in genetic manipulation of anaerobic bacteria, microbiota in vivo (mouse) studies and structural analysis of O-glycans. This fellowship will enable the fellow develop her current skill set to include methodologies and approaches so that the molecular analysis of the target enzymes can be placed within a biological context.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MUC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MUC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

InProSMod (2021)

Cholinergic and NMDAR-dependent recruitment of Layer 1 Interneuron shapes cortical motor Processing through network States Modulation

Read More  

SOCIALEU (2019)

The missing pillar. European social policy and Eurosceptic challenges (SOCIALEU)

Read More  

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More